68504-97-2

Upstream product

• 2343-29-5 5-acetyl-2-fluorobenzenesulfonamide 
• 54773-54-5 2-amino-5-iodo-benzenesulfonamide 
• 109-92-2 ethyl vinyl ether 

Downstream Products

• 68504-99-4 2-amino-5-[1-hydroxy-2-[N-(1-methyl-3-phenylpropyl)-N-(phenylmethyl)amino]ethyl]benzenesulphonamide 
• 68504-98-3 2-Amino-5-[2-bromoacetyl)benzenesulphonamide 
• 240139-78-0 2-amino-5-(1-hydroxyethyl)benzenesulfonamide 
• 240138-62-9 3-Cyclohexyl-7-(1-hydroxyethyl)-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide 
• 70958-68-8 2-Amino-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]benzenesulphonamide 

Relevant academic research and scientific papers

Novel compounds and their use as positive AMPA receptor modulators

The invention provides novel compounds represented by the general formula 5 compound represented by the formula: wherein the bond represented by the broken line may be a single, a double bond or absent; and if the bond is absent, then the nitrogen is substituted with a hydrogen and R2; X represents SO2 or C═O or CH2; Y represents —CH(R4)—, —N(R4)— or —N(R4)—CH2—, O; and the meaning of R2, R3, R4, R5, R6, R7, and R8 are as defined in the application The compounds are useful as positive modulators of the AMPA-receptor.

Phenylethanolamine therapeutic agents

Compounds of the general formula: STR1 and non-toxic physiologically acceptable salts thereof, in which R1 is a halogen atom or a group NR2 R3 ; R2 and R3, which may be the same or different, are hydrogen or (C1 -C6) straight or branched chain alkyl or R2 and R3 may, together with the nitrogen atom, form a 5 or 6 membered heterocyclic ring which may contain a further hetero atom selected from O, N or S; or R2 may be hydrogen and R3 may by group R4 CO or R4 SO2 where R4 is hydrogen or alkyl (C1-4); R5 is hydrogen or one or more halogen atoms or hydroxy or alkoxy (C1-4) groups; and X is CH2, O or a group NR6 where R6 is hydrogen or alkyl (C1-4). These compounds block β-adrenoreceptors.